According to the subgroup analysis, the incidence of high‐grade pneumonitis related to second‐generation ALK TKIs, including alectinib, ceritinib and brigatinib (1.54%, 95% CI: 0.68%–2.64%), was similar to that related to the first‐generation ALK TKI, crizotinib (1.76%, 95% CI: 0.85%–2.93%), but it was higher than that related to the third‐generation ALK TKI, lorlatinib (0.35%, 95% CI: 0.00%–1.27%). The gene discussed is ALK; the disease is pneumonitis.